JHVEPhoto/iStock Editorial by way of Getty Photos
With its This autumn 2024 outcomes on Wednesday, Novo Nordisk (NVO) introduced a brand new Part 3 trial to check its highly-anticipated weight reduction remedy, CagriSema, after a December readout failed to satisfy buyers’ lofty expectations for the next-gen candidate.
The brand new
